The FDA has granted accelerated approval to Novartis’ Vanrafia for adults with primary immunoglobulin A nephropathy (IgAN).

Novartis ( NYSE: NVS) said on Thursday that it received US FDA's accelerated approval for Vanrafia as a treatment for adults ...

Novartis (NVS) “announced the FDA has granted accelerated approval for Vanrafia, or atrasentan, a potent and selective endothelin A receptor ...

Novartis NVS obtains FDA approval of atrasentan ... a sodium-glucose co-transporter-2 (SGLT2) inhibitor. The accelerated approval from the FDA was based on a prespecified interim analysis of ...

Novartis is uniquely positioned to lead a transformation in kidney care Vanrafia was granted accelerated approval based on a prespecified interim analysis of the Phase III ALIGN study measuring ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Novartis’ Vanrafia, a treatment aimed at decreasing proteinuria in adults with primary immunoglobulin A nephropathy ...

Novartis has received accelerated approval from the US Food and Drug Administration (FDA) for Vanrafia (atrasentan), a potent and selective endothelin A (ETA) receptor antagonist, ...

FDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support ...

The FDA has granted accelerated approval to Vanrafia to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression.

Novartis is uniquely positioned to lead a transformation in kidney care Vanrafia was granted accelerated approval based on a prespecified interim analysis of the Phase III ALIGN study measuring ...